Lightwave Logic to Attend the 37th Annual ROTH Conference
Lightwave Logic Participation: Lightwave Logic, Inc. will be represented by President Tom Zelibor and CFO Jim Marcelli at the 37th Annual ROTH Conference on March 17-18, 2025, where they will engage with investors through various meetings and discussions.
Company Overview: Lightwave Logic specializes in electro-optic polymers that enhance data transmission speed and efficiency, aiming to develop advanced photonic devices for telecommunications and potential applications in generative AI.
Trade with 70% Backtested Accuracy
Analyst Views on LWLG
About LWLG
About the author
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
Lightwave Logic Reports Strong Q4 Earnings with $25.6M Revenue
- Earnings Highlights: Lightwave Logic reported a Q4 GAAP EPS of -$0.04, indicating a loss, yet achieved revenue of $25.6 million, reflecting a 32% year-over-year growth that underscores the company's robust potential in the photonics sector.
- Revenue Growth: The 32% increase in revenue compared to the previous year highlights the company's success in meeting rising market demand and driving product innovation, thereby solidifying its competitive position in the photonics market.
- Financing Initiative: Lightwave Logic announced a $35 million public offering, boosting its cash reserves to $70 million, which provides ample funding for future R&D and market expansion efforts.
- Executive Appointment: The appointment of Aref Chowdhury as Chief Technology Officer aims to leverage his extensive industry experience to drive technological innovation and product development, enhancing the company's competitive edge in the market.
Lightwave Logic Partners with Fortune Global 500 for Design Win Cycle Stage 3
- Design Collaboration Progress: Lightwave Logic announced that a Fortune Global 500 company has advanced to Stage 3 of the Design Win Cycle, marking a successful transition to prototype-to-product development after a technical evaluation, which is expected to enhance its internal silicon photonics platform capabilities.
- Technical Milestones: Key milestones for 2026 include the fabrication, processing, and testing of silicon photonic integrated circuits (PICs) integrated with electro-optic polymers, aiming to deliver solutions capable of 200Gb/s and 400Gb/s, specifically designed for hyperscale data centers or AI factory environments.
- Earnings Call Announcement: The company plans to release its fourth quarter and full year 2025 financial results before the U.S. market opens on March 5, 2026, followed by a conference call at 8:30 a.m. that will include a Q&A session, allowing investors to submit questions in advance via email.
- Platform Technology Advantage: Lightwave Logic focuses on developing electro-optic polymers to achieve ultra-high-speed data transmission with low power consumption, driving the application of next-generation photonic devices in telecommunications, data centers, and emerging AI infrastructure, showcasing its leading position in the industry.
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures falling approximately 0.2% on Tuesday morning.
Lightwave Logic Inc: Shares of Lightwave Logic Inc dropped 14.5% to $3.22 in pre-market trading following the announcement of a $35 million public offering.
Other Declining Stocks: Several other stocks also saw declines in pre-market trading, including Ascent Solar Technologies (-15.1%), Fractyl Health (-10.4%), and Ready Capital (-9%).
Market Overview: The overall market sentiment appears negative, with multiple companies reporting significant drops in their stock prices ahead of the trading day.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
Lightwave Logic Reports Strong Q4 Earnings with $25.6M Revenue
- Earnings Highlights: Lightwave Logic reported a Q4 GAAP EPS of -$0.04, indicating a loss, yet achieved revenue of $25.6 million, reflecting a 32% year-over-year growth that underscores the company's robust potential in the photonics sector.
- Revenue Growth: The 32% increase in revenue compared to the previous year highlights the company's success in meeting rising market demand and driving product innovation, thereby solidifying its competitive position in the photonics market.
- Financing Initiative: Lightwave Logic announced a $35 million public offering, boosting its cash reserves to $70 million, which provides ample funding for future R&D and market expansion efforts.
- Executive Appointment: The appointment of Aref Chowdhury as Chief Technology Officer aims to leverage his extensive industry experience to drive technological innovation and product development, enhancing the company's competitive edge in the market.
Lightwave Logic Partners with Fortune Global 500 for Design Win Cycle Stage 3
- Design Collaboration Progress: Lightwave Logic announced that a Fortune Global 500 company has advanced to Stage 3 of the Design Win Cycle, marking a successful transition to prototype-to-product development after a technical evaluation, which is expected to enhance its internal silicon photonics platform capabilities.
- Technical Milestones: Key milestones for 2026 include the fabrication, processing, and testing of silicon photonic integrated circuits (PICs) integrated with electro-optic polymers, aiming to deliver solutions capable of 200Gb/s and 400Gb/s, specifically designed for hyperscale data centers or AI factory environments.
- Earnings Call Announcement: The company plans to release its fourth quarter and full year 2025 financial results before the U.S. market opens on March 5, 2026, followed by a conference call at 8:30 a.m. that will include a Q&A session, allowing investors to submit questions in advance via email.
- Platform Technology Advantage: Lightwave Logic focuses on developing electro-optic polymers to achieve ultra-high-speed data transmission with low power consumption, driving the application of next-generation photonic devices in telecommunications, data centers, and emerging AI infrastructure, showcasing its leading position in the industry.
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures falling approximately 0.2% on Tuesday morning.
Lightwave Logic Inc: Shares of Lightwave Logic Inc dropped 14.5% to $3.22 in pre-market trading following the announcement of a $35 million public offering.
Other Declining Stocks: Several other stocks also saw declines in pre-market trading, including Ascent Solar Technologies (-15.1%), Fractyl Health (-10.4%), and Ready Capital (-9%).
Market Overview: The overall market sentiment appears negative, with multiple companies reporting significant drops in their stock prices ahead of the trading day.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
